JP2013526544A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013526544A5 JP2013526544A5 JP2013510307A JP2013510307A JP2013526544A5 JP 2013526544 A5 JP2013526544 A5 JP 2013526544A5 JP 2013510307 A JP2013510307 A JP 2013510307A JP 2013510307 A JP2013510307 A JP 2013510307A JP 2013526544 A5 JP2013526544 A5 JP 2013526544A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- optionally substituted
- disorder
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 230000004064 dysfunction Effects 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 5
- 102100038354 Metabotropic glutamate receptor 4 Human genes 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 108010038422 metabotropic glutamate receptor 4 Proteins 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 4
- 201000000980 schizophrenia Diseases 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 208000031091 Amnestic disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 206010012218 Delirium Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 claims 2
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 claims 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000002858 neurotransmitter agent Substances 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000005189 alkyl hydroxy group Chemical group 0.000 claims 1
- 230000006986 amnesia Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000000848 glutamatergic effect Effects 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000037023 motor activity Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000006576 neuronal survival Effects 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000005062 synaptic transmission Effects 0.000 claims 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33392610P | 2010-05-12 | 2010-05-12 | |
| US61/333,926 | 2010-05-12 | ||
| PCT/US2011/036308 WO2011143466A1 (en) | 2010-05-12 | 2011-05-12 | Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013526544A JP2013526544A (ja) | 2013-06-24 |
| JP2013526544A5 true JP2013526544A5 (enExample) | 2014-06-19 |
Family
ID=44914713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013510307A Withdrawn JP2013526544A (ja) | 2010-05-12 | 2011-05-12 | 複素環スルホンｍＧｌｕＲ４アロステリック増強剤、組成物、および神経機能不全を治療する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9192603B2 (enExample) |
| EP (1) | EP2568809A4 (enExample) |
| JP (1) | JP2013526544A (enExample) |
| KR (1) | KR20130079429A (enExample) |
| CN (1) | CN102939006A (enExample) |
| AU (1) | AU2011252974A1 (enExample) |
| BR (1) | BR112012028894A2 (enExample) |
| CA (1) | CA2798514A1 (enExample) |
| IL (1) | IL222854A0 (enExample) |
| MX (1) | MX2012013031A (enExample) |
| RU (1) | RU2012154447A (enExample) |
| SG (1) | SG185414A1 (enExample) |
| WO (1) | WO2011143466A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8618300B2 (en) | 2008-09-04 | 2013-12-31 | Boehringer Ingelheim International Gmbh | Indolizine inhibitors of leukotriene production |
| CA2751176A1 (en) | 2009-01-28 | 2010-08-05 | Vanderbilt University | Substituted 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| JP5690839B2 (ja) | 2009-12-04 | 2015-03-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン産生のベンゾイミダゾール阻害薬 |
| PH12013500301A1 (en) | 2010-08-16 | 2013-03-25 | Boehringer Ingelheim Int | Oxadiazole inhibitors of leukotriene production |
| EP2609092B1 (en) | 2010-08-26 | 2015-04-01 | Boehringer Ingelheim International GmbH | Oxadiazole inhibitors of leukotriene production |
| US8580825B2 (en) | 2010-09-23 | 2013-11-12 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
| AU2011305667A1 (en) | 2010-09-23 | 2013-03-21 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
| US8829200B2 (en) | 2010-10-29 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Benzimidazole inhibitors of leukotriene production |
| EP2635566B1 (en) | 2010-11-01 | 2018-05-16 | Boehringer Ingelheim International GmbH | Benzimidazole inhibitors of leukotriene production |
| WO2012082817A1 (en) | 2010-12-16 | 2012-06-21 | Boehringer Ingelheim International Gmbh | Biarylamide inhibitors of leukotriene production |
| AR089853A1 (es) | 2012-02-01 | 2014-09-24 | Boehringer Ingelheim Int | Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso |
| MX2014015265A (es) | 2012-06-14 | 2015-08-12 | Basf Se | Metodos plaguicidas que utilizan compuestos de 3-piridiltiazol sustituido y derivados para combatir plagas de animales. |
| SG11201602029VA (en) * | 2013-09-25 | 2016-04-28 | Hoffmann La Roche | Ethynyl derivatives |
| US10221172B2 (en) | 2015-01-13 | 2019-03-05 | Vanderbilt University | Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10526323B2 (en) | 2015-01-30 | 2020-01-07 | Vanderbilt University | Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10227343B2 (en) | 2015-01-30 | 2019-03-12 | Vanderbilt University | Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2016179351A1 (en) | 2015-05-05 | 2016-11-10 | Northwestern University | Treatment of levodopa-induced dyskinesias |
| WO2016202935A1 (en) | 2015-06-19 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
| US10294222B2 (en) | 2016-09-01 | 2019-05-21 | Vanderbilt University | Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10710997B2 (en) | 2016-09-01 | 2020-07-14 | Vanderbilt University | Isoquinoline amide and isoquinoline amide-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2018089544A1 (en) | 2016-11-08 | 2018-05-17 | Vanderbilt University | Isoquinoline amine compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10968227B2 (en) | 2016-11-08 | 2021-04-06 | Vanderbilt University | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| JP7101177B2 (ja) | 2017-01-10 | 2022-07-14 | バイエル・アクチエンゲゼルシヤフト | 有害生物防除剤としてのヘテロサイクレン誘導体 |
| MX2019008230A (es) | 2017-01-10 | 2019-10-24 | Bayer Ag | Derivados heterociclicos como agentes de control de plagas. |
| US11319304B2 (en) | 2017-06-28 | 2022-05-03 | Vanderbilt University | Pyridine quinoline compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| EA202090467A1 (ru) | 2017-08-16 | 2020-06-18 | Вандербилт Юниверсити | ИНДАЗОЛОВЫЕ СОЕДИНЕНИЯ КАК АЛЛОСТЕРИЧЕСКИЕ ПОТЕНЦИАТОРЫ mGLuR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ |
| SI3752501T1 (sl) | 2018-02-13 | 2023-08-31 | Gilead Sciences, Inc. | Inhibitorji pd-1/pd-l1 |
| WO2019169193A1 (en) | 2018-03-01 | 2019-09-06 | Annapurna Bio Inc. | Compounds and compositions for treating conditions associated with apj receptor activity |
| CA3093130C (en) | 2018-04-19 | 2023-10-17 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| SI3820572T1 (sl) | 2018-07-13 | 2023-12-29 | Gilead Sciences, Inc. | Inhibitorji pd-1/pd-l1 |
| JP7158577B2 (ja) | 2018-10-24 | 2022-10-21 | ギリアード サイエンシーズ， インコーポレイテッド | Ｐｄ－１／ｐｄ－ｌ１阻害剤 |
| CA3134635A1 (en) | 2019-04-03 | 2020-10-08 | Aligos Therapeutics, Inc. | Pyrrole compounds |
| AU2020407664A1 (en) | 2019-12-20 | 2022-08-18 | Tenaya Therapeutics, Inc. | Fluoroalkyl-oxadiazoles and uses thereof |
| US20230247994A1 (en) | 2020-07-02 | 2023-08-10 | Bayer Aktiengesellschaft | Heterocyclene derivatives as pest control agents |
| EP4333841A1 (en) | 2021-05-04 | 2024-03-13 | Tenaya Therapeutics, Inc. | 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE21393T1 (de) | 1982-01-22 | 1986-08-15 | Basf Ag | Thiadiazolderivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses. |
| US6262096B1 (en) | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| US6040321A (en) | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| US6162791A (en) | 1998-03-02 | 2000-12-19 | Apotex Inc. | Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes |
| US6468977B1 (en) | 1998-03-02 | 2002-10-22 | Apotex Inc. | Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes |
| JP2002506858A (ja) | 1998-03-19 | 2002-03-05 | ファルマシア・アンド・アップジョン・カンパニー | Ｃｍｖ感染症の治療に有用な１，３，４−チアジアゾール |
| ES2257461T3 (es) | 2000-12-21 | 2006-08-01 | Bristol-Myers Squibb Company | Inhibidores de tiazolilo de tirosina quinasas de la familia tec. |
| WO2005007096A2 (en) | 2003-07-11 | 2005-01-27 | Merck & Co., Inc. | Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator |
| EP1983980A4 (en) | 2006-01-25 | 2010-05-05 | Synta Pharmaceuticals Corp | THIAZOL AND THIADIAZOL COMPOUNDS FOR USES IN RELATION TO INFLAMMATION AND IMMUNITY |
| US7951824B2 (en) * | 2006-02-17 | 2011-05-31 | Hoffman-La Roche Inc. | 4-aryl-pyridine-2-carboxyamide derivatives |
| EP2081905B1 (en) | 2006-07-28 | 2012-09-12 | Boehringer Ingelheim International GmbH | Sulfonyl compounds which modulate the cb2 receptor |
| MX2009002888A (es) | 2006-09-25 | 2009-03-31 | Boehringer Ingelheim Int | Compuestos que modulan el receptor cb2. |
| US20100029685A1 (en) * | 2006-10-25 | 2010-02-04 | Neurosearch A/S | Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators |
| GB0622202D0 (en) | 2006-11-07 | 2006-12-20 | Addex Pharmaceuticals Sa | Novel compounds |
| GB0713686D0 (en) | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| WO2010033350A1 (en) | 2008-09-16 | 2010-03-25 | Merck & Co., Inc. | Sulfonamide derivative metabotropic glutamate r4 ligands |
-
2011
- 2011-05-12 EP EP11781297.4A patent/EP2568809A4/en not_active Withdrawn
- 2011-05-12 MX MX2012013031A patent/MX2012013031A/es not_active Application Discontinuation
- 2011-05-12 SG SG2012081162A patent/SG185414A1/en unknown
- 2011-05-12 WO PCT/US2011/036308 patent/WO2011143466A1/en not_active Ceased
- 2011-05-12 CA CA2798514A patent/CA2798514A1/en not_active Abandoned
- 2011-05-12 CN CN201180029055XA patent/CN102939006A/zh active Pending
- 2011-05-12 RU RU2012154447/04A patent/RU2012154447A/ru not_active Application Discontinuation
- 2011-05-12 BR BR112012028894A patent/BR112012028894A2/pt not_active IP Right Cessation
- 2011-05-12 KR KR1020127032242A patent/KR20130079429A/ko not_active Withdrawn
- 2011-05-12 JP JP2013510307A patent/JP2013526544A/ja not_active Withdrawn
- 2011-05-12 US US13/697,783 patent/US9192603B2/en active Active
- 2011-05-12 AU AU2011252974A patent/AU2011252974A1/en not_active Abandoned
-
2012
- 2012-11-05 IL IL222854A patent/IL222854A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013526544A5 (enExample) | ||
| JP2013519684A5 (enExample) | ||
| JP2013519685A5 (enExample) | ||
| RU2012139491A (ru) | Бензизоксазолы и азабензизоксазолы как аллостерические потенциаторы mglur4, композиции и способы лечения неврологических дисфункций | |
| RU2012154447A (ru) | Гетероциклические сульфоновые аллостерические потенциаторы mglur4, композиции и способы лечения неврологических дисфункций | |
| JP2013545730A5 (enExample) | ||
| JP2013526609A5 (enExample) | ||
| RU2012114770A (ru) | АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ | |
| JP2011515482A5 (enExample) | ||
| RU2012121631A (ru) | АРИЛ- И ГЕТЕРОАРИЛСУЛЬФОНЫ КАК АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ | |
| HRP20120317T1 (hr) | Spojevi morfinana | |
| JP2015501783A5 (enExample) | ||
| JP2016185995A5 (enExample) | ||
| JP2015529234A5 (enExample) | ||
| JP2013522326A5 (enExample) | ||
| JP2013536833A5 (enExample) | ||
| JP2013503909A5 (enExample) | ||
| JP2014532730A5 (ja) | オピオイド受容体の調節物質およびそれを含む薬学的組成物 | |
| JP2020503246A5 (enExample) | ||
| JP2020531454A5 (enExample) | ||
| JP2012531402A5 (enExample) | ||
| JP2014533272A5 (enExample) | ||
| JP2015516988A5 (enExample) | ||
| JP2014509653A5 (enExample) | ||
| SG11201407973SA (en) | Prodrug of fluorine-containing amino acid |